Ignite Creation Date:
2024-07-17 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463665
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-11
Brief Title:
Efficacy Safety of Olvimulogene Nanivacirepvec Platinum-doublet Physicians Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Sponsor:
Genelux Corporation
Organization:
Genelux Corporation
Organization Data
Organization:
Genelux Corporation
Class:
INDUSTRY
Study ID:
Olvi-Vec-NSCLC-025
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genelux Corporation
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Newsoara Biopharma Co Ltd | INDUSTRY |